Cargando…

Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report

Inflammatory myofibroblastic tumor (IMT) is a very rare subtype of sarcoma, which frequently harbor chromosomal rearrangements, including anaplastic lymphoma kinase (ALK) rearrangements (almost 50% of the IMTs) and other kinase fusions such as ROS1. ROS1 fusions are present in about 10% of IMT, almo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comandini, Danila, Catalano, Fabio, Grassi, Massimiliano, Pesola, Guido, Bertulli, Rossella, Guadagno, Antonio, Spina, Bruno, Mascherini, Matteo, De Cian, Franco, Pistoia, Federico, Rebuzzi, Sara Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239351/ https://www.ncbi.nlm.nih.gov/pubmed/34211840 http://dx.doi.org/10.3389/fonc.2021.658327

Ejemplares similares

Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Neoadjuvant crizotinib in ALK-rearranged inflammatory myofibroblastic tumor of the urinary bladder: A case report
por: Nagumo, Yoshiyuki, et al.
Publicado: (2018)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
por: Suryavanshi, Moushumi, et al.
Publicado: (2017)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

A case of ROS1‐rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib
por: Tachi, Hiroaki, et al.
Publicado: (2020)

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report
por: Yang, Guangdie, et al.
Publicado: (2021)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
por: Ogata, Misato, et al.
Publicado: (2018)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Successful Treatment of ROS1-rearranged Lung Cancer Complicated by Hypertrophic Pulmonary Osteoarthropathy with Crizotinib Therapy
por: Katsurada, Naoko, et al.
Publicado: (2019)

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements
por: Zhang, Yongchang, et al.
Publicado: (2022)

Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients
por: Zhang, Huixian, et al.
Publicado: (2023)

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib
por: Mansfield, A. S., et al.
Publicado: (2016)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report
por: Begum, Parvin, et al.
Publicado: (2022)

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort
por: Gibson, Amanda J. W., et al.
Publicado: (2022)

Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice
por: Liu, Chang, et al.
Publicado: (2019)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
por: Mehta, Anurag, et al.
Publicado: (2020)

Crizotinib for ROS1‐rearranged lung cancer and pulmonary tumor thrombotic microangiopathy under venoarterial extracorporeal membrane oxygenation
por: Aoyama, Daisetsu, et al.
Publicado: (2022)

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
por: Schneider, Jaime L., et al.
Publicado: (2022)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Inflammatory Myofibroblastic Tumor: A Rare Presentation and an Effective Treatment with Crizotinib
por: Khalil, Sumaira, et al.
Publicado: (2020)

Small cell transformation in crizotinib‐resistant ROS1‐rearranged non‐small cell lung cancer with retention of ROS1 fusion: A case report
por: Wu, Chi‐Hao, et al.
Publicado: (2021)

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report
por: Zhao, Shikang, et al.
Publicado: (2021)

Epithelioid Inflammatory Myofibroblastic Sarcoma With Poor Response to Crizotinib: A Case Report
por: Aminimoghaddam, Soheila, et al.
Publicado: (2023)

First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020)

Molecular Tailored Therapeutic Options for Advanced Gastrointestinal Stromal Tumors (GISTs): Current Practice and Future Perspectives
por: Catalano, Fabio, et al.
Publicado: (2023)

Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer
por: Zeng, Liang, et al.
Publicado: (2018)

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report
por: Tanimura, Mai, et al.
Publicado: (2021)

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada
por: Beca, Jaclyn M., et al.
Publicado: (2021)

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
por: Shaw, A T, et al.
Publicado: (2019)

TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma
por: Xu, Caihua, et al.
Publicado: (2020)

Case Report: Two Rare Cases of Complete Metabolic Response to Crizotinib in Patients With Rearranged ROS1 and ALK Metastatic Non-small Lung Cancer
por: Amrane, Karim, et al.
Publicado: (2021)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Efficiency of Crizotinib on an ALK-Positive Inflammatory Myofibroblastic Tumor of the Central Nervous System: A Case Report
por: Chennouf, Anas, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_tb5djsv57f9h9c0lvukvr4bc2o